Rabbit Polyclonal NQO1 antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Synthetic Peptide within Human NQO1 aa 200-250.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine)
WB | IHC-P | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/3000.00000 | Notes In some tested cell lines double bands (~26-34kDa) are seen: 293T, A431, H1299, HeLa, HepG2. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/500.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/200.00000 | Notes - |
Select an associated product type
Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (By similarity) (PubMed:8999809, PubMed:9271353). Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion (PubMed:15102952, PubMed:8999809, PubMed:9271353). Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential (PubMed:8999809). Acts as a gatekeeper of the core 20S proteasome known to degrade proteins with unstructured regions. Upon oxidative stress, interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way and inhibits their ubiquitin-independent degradation by the 20S proteasome (PubMed:15687255, PubMed:28291250).
DIA4, NMOR1, NQO1, NAD(P)H dehydrogenase [quinone] 1, Azoreductase, DT-diaphorase, Menadione reductase, NAD(P)H:quinone oxidoreductase 1, Phylloquinone reductase, Quinone reductase 1, DTD, QR1
Rabbit Polyclonal NQO1 antibody. Suitable for WB, IHC-P, ICC/IF and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Synthetic Peptide within Human NQO1 aa 200-250.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine)
NQO1 also known as NAD(P)H:quinone oxidoreductase 1 is a cytosolic enzyme involved in two-electron reduction processes. This protein plays a role in detoxification transforming quinones into less reactive and harmful hydroquinones. NQO1 has a molecular weight of approximately 31 kDa and is present in various tissues with high expression in the liver and lungs. Sometimes called DT-diaphorase it contributes to antioxidant protection within cells and assists in the stabilization of other proteins such as p53.
NQO1 serves a protective function against oxidative stress by reducing quinones and preventing redox cycling that generates reactive oxygen species. Part of a critical network its function integrates with the cellular defense mechanism assisting in maintaining cellular homeostasis. NQO1 helps metabolize xenobiotics and is associated with phase II detoxification working alongside enzymes like glutathione S-transferases but is not part of a complex.
NQO1 is an important component of the antioxidant defense pathway participating in the direct enzymatic reduction of quinones protecting cells from oxidative damage. It also interfaces with the KEAP1-NRF2 pathway where the NQO1 gene is regulated by the NRF2 transcription factor that upregulates its expression in response to oxidative stress. NQO1 interlinks with proteins such as p53 through pathways related to apoptotic regulation and cellular stress responses.
Mutations or altered expression of NQO1 have correlations with cancer development and progression notably in liver and lung cancers. This protein's stability influences cancer cell survival particularly under oxidative stress or chemotherapeutic treatments. NQO1 also exhibits links to Alzheimer's disease where its potential role in neuroprotection against oxidative damage draws investigation relating it to proteins like tau and amyloid-beta.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
12% SDS PAGE
All lanes: Western blot - Anti-NQO1 antibody (ab97385) at 1/1000 dilution
Lane 1: MOLT4 whole cell lysate at 30 µg
Lane 2: Raji whole cell lysate at 30 µg
Predicted band size: 31 kDa
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human ovarian endometriosis tissue, staining NQO1 with ab97385.
Antigen retrieval was performed in sodium citrate buffer in a microwave oven. Samples were blocked with rabbit serum for one hour before incubating overnight with primary antibody (1/200). Stainined was detected using DAB.
Immunofluorescence analysis of paraformaldehyde-fixed HeLa cells, using ab97385 at 1/200 dilution. Lower image merged with DNA probe.
Immunohistochemical analysis of paraffin-embedded CL1-0 xenograft, using ab97385 at 1/500 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com